Acamprosate committee review
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryForest and Lipha's acamprosate studies demonstrate sufficient efficacy to support approval of the drug for maintenance therapy for alcohol abstinence, FDA's Psychopharmacologic Drugs Advisory Committee concludes in an eight to two vote at its May 10 meetin
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.